Pamela Sankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pamela Sankar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Nora L. Jones
3 shared publications- Jon F. Merz
University of Pennsylvania
2 shared publications Mildred K. Cho
Stanford Center for Biomedical Ethics, Stanford University, Stanford, California
2 shared publicationsBarbara Koenig
1 shared publicationCeleste M. Condit
1 shared publicationG Jenkins
Johns Hopkins University, Phoebe R Berman Bioethics Institute, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 12 May 2015
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 7 (1) , 1-9
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants
Introduction: The objective of this study was to develop a process to maximize the safety and effectiveness of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults participating in Alzheimer’s disease secondary prevention studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study. Methods: Using a modified Delphi Method to develop consensus on best practices, we gathered and analyzed data over three rounds from experts in two relevant fields: informed consent for genetic testing or human amyloid imaging. Results: Experts reached consensus on (1) text for a brochure that describes amyloid imaging to a person who is considering whether to undergo such imaging in the context of a clinical trial, and (2) a process for amyloid PET result disclosure within such trials. Recommendations included: During consent, potential participants should complete an educational session, where they receive verbal and written information covering what is known and unknown about amyloid imaging, including possible results and their meaning, implications of results for risk of future cognitive decline, and information about Alzheimer’s and risk factors. Participants should be screened for anxiety and depression to determine suitability to receive amyloid imaging information. The person conducting the sessions should check comprehension and be skilled in communication and recognizing distress. Imaging should occur on a separate day from consent, and disclosure on a separate day from imaging. Disclosure should occur in person, with time for questions. At disclosure, investigators should assess mood and willingness to receive results, and provide a written results report. Telephone follow-up within a few days should assess the impact of disclosure, and periodic scheduled assessments of depression and anxiety, with additional monitoring and follow-up for participants showing distress, should be performed. Conclusions: We developed a document for use with potential study participants to describe the process of amyloid imaging and the implications of amyloid imaging results; and a disclosure process with attention to ongoing monitoring of both mood and safety to receive this information. This document and process will be used in the A4 Study and can be adapted for other research settings.
- 12 May 2015
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 7 (1) , 1-9
Open AccessDevelopment of a process to disclose amyloid imaging results to cognitively normal older adult research participants
Introduction: The objective of this study was to develop a process to maximize the safety and effectiveness of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults participating in Alzheimer’s disease secondary prevention studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study. Methods: Using a modified Delphi Method to develop consensus on best practices, we gathered and analyzed data over three rounds from experts in two relevant fields: informed consent for genetic testing or human amyloid imaging. Results: Experts reached consensus on (1) text for a brochure that describes amyloid imaging to a person who is considering whether to undergo such imaging in the context of a clinical trial, and (2) a process for amyloid PET result disclosure within such trials. Recommendations included: During consent, potential participants should complete an educational session, where they receive verbal and written information covering what is known and unknown about amyloid imaging, including possible results and their meaning, implications of results for risk of future cognitive decline, and information about Alzheimer’s and risk factors. Participants should be screened for anxiety and depression to determine suitability to receive amyloid imaging information. The person conducting the sessions should check comprehension and be skilled in communication and recognizing distress. Imaging should occur on a separate day from consent, and disclosure on a separate day from imaging. Disclosure should occur in person, with time for questions. At disclosure, investigators should assess mood and willingness to receive results, and provide a written results report. Telephone follow-up within a few days should assess the impact of disclosure, and periodic scheduled assessments of depression and anxiety, with additional monitoring and follow-up for participants showing distress, should be performed. Conclusions: We developed a document for use with potential study participants to describe the process of amyloid imaging and the implications of amyloid imaging results; and a disclosure process with attention to ongoing monitoring of both mood and safety to receive this information. This document and process will be used in the A4 Study and can be adapted for other research settings.
- Open Access
- 7 March 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (9) , 961-970
Race and ethnicity in genetic research
Use of race and ethnicity terms in genetic research continues to generate controversy. Despite differing opinions about their basis or relevance, there is some agreement that investigators using these terms should: explain why the terms or categories were used, define them carefully, and apply them consistently. An important question is whether these recommendations are reflected in practice. Here we addressed this question based on 330 randomly selected articles published between 2001 and 2004 that reported on genetic research and used one or more words from a defined list of race, ethnicity, or population terms. The recommendation that authors using race or ethnicity terms explain the basis for assigning them to study populations was met infrequently (9.1%), and articles that used race and ethnicity as variables were no more likely than those that used them only to label a sample to provide these details. No article defined or discussed the concepts of race or ethnicity. With limited exceptions, current practice does not reflect repeated recommendations for using race or ethnicity terms in genetic research. This study provides a baseline against which to measure future trends.
- 7 March 2007
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (9) , 961-970
Open AccessRace and ethnicity in genetic research
Use of race and ethnicity terms in genetic research continues to generate controversy. Despite differing opinions about their basis or relevance, there is some agreement that investigators using these terms should: explain why the terms or categories were used, define them carefully, and apply them consistently. An important question is whether these recommendations are reflected in practice. Here we addressed this question based on 330 randomly selected articles published between 2001 and 2004 that reported on genetic research and used one or more words from a defined list of race, ethnicity, or population terms. The recommendation that authors using race or ethnicity terms explain the basis for assigning them to study populations was met infrequently (9.1%), and articles that used race and ethnicity as variables were no more likely than those that used them only to label a sample to provide these details. No article defined or discussed the concepts of race or ethnicity. With limited exceptions, current practice does not reflect repeated recommendations for using race or ethnicity terms in genetic research. This study provides a baseline against which to measure future trends.
- 1 December 2006
- Published by Taylor & Francis in New Genetics and Society
- Vol. 25 (3) , 249-264
Hasty generalisation and exaggerated certainties: reporting genetic findings in health disparities research
In the United States, research that examines potential genetic contributions to health disparities often relies on racial categories. Some see benefit in this research especially for conditions where disparities in health status seem strongly associated with racial identity, such as heart disease and prostate cancer. But this research calls for close scrutiny. First, despite common optimism about genetic research, it may not be the most productive way to examine health disparities. And second, this research has the potential to contribute to racial stereotypes, arguably a prime cause of the health disparities the genetic research actually seeks to ameliorate. Two articles reporting results about genetics and heart disease are used to illustrate these concerns. Both report strong correlations between increased vulnerability to heart disease and black racial identity. Despite serious sampling and analysis problems in these articles, the findings rapidly entered the scientific and popular literature. A possible reason for their ready acceptance is their congruence with stereotypes that attribute poor health and genetic inferiority to minority US populations.
- 1 December 2006
- Published by Taylor & Francis in New Genetics and Society
- Vol. 25 (3) , 249-264
Hasty generalisation and exaggerated certainties: reporting genetic findings in health disparities research
In the United States, research that examines potential genetic contributions to health disparities often relies on racial categories. Some see benefit in this research especially for conditions where disparities in health status seem strongly associated with racial identity, such as heart disease and prostate cancer. But this research calls for close scrutiny. First, despite common optimism about genetic research, it may not be the most productive way to examine health disparities. And second, this research has the potential to contribute to racial stereotypes, arguably a prime cause of the health disparities the genetic research actually seeks to ameliorate. Two articles reporting results about genetics and heart disease are used to illustrate these concerns. Both report strong correlations between increased vulnerability to heart disease and black racial identity. Despite serious sampling and analysis problems in these articles, the findings rapidly entered the scientific and popular literature. A possible reason for their ready acceptance is their congruence with stereotypes that attribute poor health and genetic inferiority to minority US populations.
- 1 April 2006
- Published by S. Karger AG in Public Health Genomics
- Vol. 9 (2) , 78-86
How Do Women Decide? Accepting or Declining BRCA1/2 Testing in a Nationwide Clinical Sample in the United States
Objective: To examine the role of the practitioner, informed consent, and genetic counseling in genetic testing decisions and to assess their relative influence on women’s decision to have clinical BRCA1/2 testing. Methods: Qualitative study using in-depth open-ended interviews with 68 women who had considered clinical BRCA1/2 testing. Results: Slightly less than half of the women who had considered BRCA1/2 testing were found to have had a clear and preexisting desire to test or not to test, irrespective of practitioner attitude or advice. Conclusion: The decision to accept or decline genetic testing is the result of a complex process that goes beyond interactions between health care providers and patients, indicating a caution against exclusive reliance on informed consent or counseling encounters.
- 1 April 2006
- Published by S. Karger AG in Public Health Genomics
- Vol. 9 (2) , 78-86
How Do Women Decide? Accepting or Declining BRCA1/2 Testing in a Nationwide Clinical Sample in the United States
Objective: To examine the role of the practitioner, informed consent, and genetic counseling in genetic testing decisions and to assess their relative influence on women’s decision to have clinical BRCA1/2 testing. Methods: Qualitative study using in-depth open-ended interviews with 68 women who had considered clinical BRCA1/2 testing. Results: Slightly less than half of the women who had considered BRCA1/2 testing were found to have had a clear and preexisting desire to test or not to test, irrespective of practitioner attitude or advice. Conclusion: The decision to accept or decline genetic testing is the result of a complex process that goes beyond interactions between health care providers and patients, indicating a caution against exclusive reliance on informed consent or counseling encounters.
- Open Access
- 14 November 2005
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (20) , 2378-2383
To Tell or Not to Tell
Effective treatment relies on patient disclosure of relevant information. Medical confidentiality protections are meant to encourage disclosure, and typically patients do disclose what is needed. However, under what circumstances patients decide not to disclose and whether these decisions relate to confidentiality protections, or to other factors, is not well understood, especially for the primary care patient.
- 14 November 2005
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (20) , 2378-2383
Open AccessTo Tell or Not to Tell
Effective treatment relies on patient disclosure of relevant information. Medical confidentiality protections are meant to encourage disclosure, and typically patients do disclose what is needed. However, under what circumstances patients decide not to disclose and whether these decisions relate to confidentiality protections, or to other factors, is not well understood, especially for the primary care patient.
- Open Access
- 30 August 2005
- Published by BMJ in Journal of Medical Ethics
- Vol. 31 (9) , 499-504
A qualitative study of women’s views on medical confidentiality
Context:The need to reinvigorate medical confidentiality protections is recognised as an important objective in building patient trust necessary for successful health outcomes. Little is known about patient understanding and expectations from medical confidentiality.Objective:To identify and describe patient views of medical confidentiality and to assess provisionally the range of these views.Design:Qualitative study using indepth, open ended face-to-face interviews.Setting:Southeastern Pennsylvania and southern New Jersey, USA.Participants:A total of 85 women interviewed at two clinical sites and three community/research centres.Main outcome measures:Subjects’ understanding of medical confidentiality, beliefs about the handling of confidential information and concerns influencing disclosure of information to doctors.Results:The subjects defined medical confidentiality as the expectation that something done or said would be kept “private” but differed on what information was confidential and the basis and methods for protecting information. Some considered all medical information as confidential and thought confidentiality protections functioned to limit its circulation to medical uses and reimbursement needs. Others defined only sensitive or potentially stigmatising information as confidential. Many of these also defined medical confidentiality as a strict limit prohibiting information release, although some noted that specific permission or urgent need could override this limit.Conclusions:Patients share a basic understanding of confidentiality as protection of information, but some might have expectations that are likely not met by current practice nor anticipated by doctors. Doctors should recognise that patients might have their own medical confidentiality models. They should address divergences from current practice and provide support to those who face emotional or practical obstacles to self-revelation.
- 30 August 2005
- Published by BMJ in Journal of Medical Ethics
- Vol. 31 (9) , 499-504
Open AccessA qualitative study of women’s views on medical confidentiality
Context:The need to reinvigorate medical confidentiality protections is recognised as an important objective in building patient trust necessary for successful health outcomes. Little is known about patient understanding and expectations from medical confidentiality.Objective:To identify and describe patient views of medical confidentiality and to assess provisionally the range of these views.Design:Qualitative study using indepth, open ended face-to-face interviews.Setting:Southeastern Pennsylvania and southern New Jersey, USA.Participants:A total of 85 women interviewed at two clinical sites and three community/research centres.Main outcome measures:Subjects’ understanding of medical confidentiality, beliefs about the handling of confidential information and concerns influencing disclosure of information to doctors.Results:The subjects defined medical confidentiality as the expectation that something done or said would be kept “private” but differed on what information was confidential and the basis and methods for protecting information. Some considered all medical information as confidential and thought confidentiality protections functioned to limit its circulation to medical uses and reimbursement needs. Others defined only sensitive or potentially stigmatising information as confidential. Many of these also defined medical confidentiality as a strict limit prohibiting information release, although some noted that specific permission or urgent need could override this limit.Conclusions:Patients share a basic understanding of confidentiality as protection of information, but some might have expectations that are likely not met by current practice nor anticipated by doctors. Doctors should recognise that patients might have their own medical confidentiality models. They should address divergences from current practice and provide support to those who face emotional or practical obstacles to self-revelation.
- Open Access
- 1 January 2005
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 24 (Suppl1) , W5-455
BiDil: Race Medicine Or Race Marketing?
Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irrespective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the culiarities of U.S. patent law and willingness exploit race to gain commercial and regulatory advantage.
- 1 January 2005
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 24 (Suppl1) , W5-455
Open AccessBiDil: Race Medicine Or Race Marketing?
Recent Food and Drug Administration (FDA) approval of the first drug with a race-specific indication has fueled the controversy over the meaning of race and ethnicity and raised questions over whether this move should be seen as an advance or a setback in the struggle to address disparities in health status associated with race. The drug, BiDil, combines two generics long recognized as benefiting patients with heart failure, irrespective of race or ethnicity. The push to bring these drugs to market as a race-specific treatment was motivated by the culiarities of U.S. patent law and willingness exploit race to gain commercial and regulatory advantage.
- 23 June 2004
- Published by American Medical Association (AMA) in JAMA
- Vol. 291 (24) , 2985-2989
Genetic Research and Health Disparities
Alleviating health disparities in the United States is a goal with broad support. Medical research undertaken to achieve this goal typically adopts the well-established perspective that racial discrimination and poverty are the major contributors to unequal health status. However, the suggestion is increasingly made that genetic research also has a significant role to play in alleviating this problem, which likely overstates the importance of genetics as a factor in health disparities. Overemphasis on genetics as a major explanatory factor in health disparities could lead researchers to miss factors that contribute to disparities more substantially and may also reinforce racial stereotyping, which may contribute to disparities in the first place. Arguments that promote genetics research as a way to help alleviate health disparities are augmented by several factors, including research funding initiatives and the distinct demographic patterns of health disparities in the United States.
- 23 June 2004
- Published by American Medical Association (AMA) in JAMA
- Vol. 291 (24) , 2985-2989
Genetic Research and Health Disparities
Alleviating health disparities in the United States is a goal with broad support. Medical research undertaken to achieve this goal typically adopts the well-established perspective that racial discrimination and poverty are the major contributors to unequal health status. However, the suggestion is increasingly made that genetic research also has a significant role to play in alleviating this problem, which likely overstates the importance of genetics as a factor in health disparities. Overemphasis on genetics as a major explanatory factor in health disparities could lead researchers to miss factors that contribute to disparities more substantially and may also reinforce racial stereotyping, which may contribute to disparities in the first place. Arguments that promote genetics research as a way to help alleviate health disparities are augmented by several factors, including research funding initiatives and the distinct demographic patterns of health disparities in the United States.
- 1 August 2003
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 18 (8) , 659-669
Patient perspectives on medical confidentiality
OBJECTIVE: To lay the groundwork for a better understanding of patient views on medical confidentiality. DESIGN: Studies were found by searching MEDLINE, BIOETHICSLINE, and selected bibliographies. Articles concerning physician perspectives or implications of legal and administrative regulations were excluded. Only peer-reviewed journal articles reporting original research on patients’ confidentiality views and conduct were included. MAIN RESULTS: Many patients are unaware of or misunderstand their legal or ethical right to medical confidentiality protections, which leads them to both over- and underestimate confidentiality protections. The possibility that medical information might be revealed, intentionally or not, to acquaintances in a clinic or other social community troubles patients as much as information release to insurers or employers. A significant minority of patients distrust confidentiality protections, leading some to report that they delay or forgo medical care. If doubtful that confidentiality will be upheld, patients will act independently to protect information. CONCLUSIONS: Our review found a wider variety of understandings and beliefs about medical confidentiality among patients than are often indicated in the writings of practitioners or legal experts. As medical confidentiality regulations evolve, these differences need to be recognized and accounted for in interactions between practitioners and patients.
- 1 August 2003
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 18 (8) , 659-669
Patient perspectives on medical confidentiality
OBJECTIVE: To lay the groundwork for a better understanding of patient views on medical confidentiality. DESIGN: Studies were found by searching MEDLINE, BIOETHICSLINE, and selected bibliographies. Articles concerning physician perspectives or implications of legal and administrative regulations were excluded. Only peer-reviewed journal articles reporting original research on patients’ confidentiality views and conduct were included. MAIN RESULTS: Many patients are unaware of or misunderstand their legal or ethical right to medical confidentiality protections, which leads them to both over- and underestimate confidentiality protections. The possibility that medical information might be revealed, intentionally or not, to acquaintances in a clinic or other social community troubles patients as much as information release to insurers or employers. A significant minority of patients distrust confidentiality protections, leading some to report that they delay or forgo medical care. If doubtful that confidentiality will be upheld, patients will act independently to protect information. CONCLUSIONS: Our review found a wider variety of understandings and beliefs about medical confidentiality among patients than are often indicated in the writings of practitioners or legal experts. As medical confidentiality regulations evolve, these differences need to be recognized and accounted for in interactions between practitioners and patients.
- 1 February 2003
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 54 (1) , 393-407
Genetic Privacy
During the past 10 years, the number of genetic tests performed more than tripled, and public concern about genetic privacy emerged. The majority of states and the U.S. government have passed regulations protecting genetic information. However, research has shown that concerns about genetic privacy are disproportionate to known instances of information misuse. Beliefs in genetic determinacy explain some of the heightened concern about genetic privacy. Discussion of the debate over genetic testing within families illustrates the most recent response to genetic privacy concerns.
- 1 February 2003
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 54 (1) , 393-407
Genetic Privacy
During the past 10 years, the number of genetic tests performed more than tripled, and public concern about genetic privacy emerged. The majority of states and the U.S. government have passed regulations protecting genetic information. However, research has shown that concerns about genetic privacy are disproportionate to known instances of information misuse. Beliefs in genetic determinacy explain some of the heightened concern about genetic privacy. Discussion of the debate over genetic testing within families illustrates the most recent response to genetic privacy concerns.